We are live on ! Find out more
DCMIC

Decheng Capital Management III (Cayman) Portfolio holdings

AUM $300M
1-Year Est. Return 15.74%
This Fund
S&P 500
This Quarter Est. Return
+0.4%
1 Year Est. Return
+15.74%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$276M
AUM Growth
+$12.1M
Cap. Flow
+$38.2M
Cap. Flow %
13.86%
Top 10 Hldgs %
78.99%
Holding
28
New
3
Increased
5
Reduced
1
Closed
2

Top Buys

Rank Stock Value
1
ALPN
Alpine Immune Sciences Inc
ALPN
+$16.5M
2
APGN
Apexigen, Inc. Common Stock
APGN
+$15.4M
3
SGEN
Seagen Inc. Common Stock
SGEN
+$3.75M
4
ALBO
Albireo Pharma Inc
ALBO
+$2.17M
5
TXG icon
10x Genomics
TXG
+$2.12M

Top Sells

Rank Stock Value
1
ILMN icon
Illumina
ILMN
+$4.9M
2
MASS icon
908 Devices
MASS
+$412K
3
OMIC
Singular Genomics Systems, Inc. Common Stock
OMIC
+$76K

Sector Composition

Rank Sector Weight
1 Healthcare 99.34%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MASS icon
26
908 Devices
MASS
$415M
– –
-20,000
Closed -$412K
OMIC
27
DELISTED
Singular Genomics Systems, Inc. Common Stock
OMIC
– –
-667
Closed -$76K
1
2

Similar funds

IBT
International Biotechnology Trust London, United Kingdom $297M AUM 17.25% 1-Year Est. Return
3LCM
3D/L Capital Management Hartford, Connecticut $308M AUM 13.67% 1-Year Est. Return
DT
Daniels + Tansey Wilmington, Delaware $289M AUM 18.06% 1-Year Est. Return
SFG
Steward Financial Group Colleyville, Texas $315M AUM 13.78% 1-Year Est. Return
TFA
Triad Financial Advisors Greensboro, North Carolina $284M AUM 14.95% 1-Year Est. Return
AEPLI
AH Equity Partners LSV I Menlo Park, California $315M AUM 9.31% 1-Year Est. Return
CC
Chanos & Company New York $318M AUM 4.62% 1-Year Est. Return
KBC
Key Bridge Compliance $319M AUM

Decheng Capital Management III (Cayman)'s Q3 2022 Portfolio in Review

As of Q3 2022, Decheng Capital Management III (Cayman) held 28 positions worth $276M, up 4.6% from $264M the previous quarter. Its ten largest holdings account for 79% of the portfolio.

Decheng Capital Management III (Cayman) deployed $38.2M of net new capital in Q3 2022, opening 3 new positions and adding to 5 existing holdings. Its largest new stake was Apexigen, Inc. Common Stock: 1,894,551 shares worth $5.12M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier.

On the sell side, the largest reduction was Illumina, an estimated $4.9M trimmed.

  • Decheng Capital Management III (Cayman)'s largest Q3 2022 buy was Apexigen, Inc. Common Stock: 1,894,551 shares worth $5.12M.
  • Decheng Capital Management III (Cayman) added most to Alpine Immune Sciences Inc in Q3 2022, an estimated $16.5M increase.
  • Decheng Capital Management III (Cayman)'s biggest Q3 2022 reduction was Illumina, cutting an estimated $4.9M.
  • Decheng Capital Management III (Cayman) fully exited 908 Devices in Q3 2022, selling an estimated $412K.
  • Decheng Capital Management III (Cayman)'s ten largest holdings make up 79% of its $276M portfolio in Q3 2022.
  • Decheng Capital Management III (Cayman) opened 3 new positions and closed 2 in Q3 2022.
  • Decheng Capital Management III (Cayman)'s portfolio value rose 4.6% quarter-over-quarter to $276M.

Based on Decheng Capital Management III (Cayman)'s 13F filing for Q3 2022, filed 8 Nov 2022.